ELVN
NASDAQ
US
Enliven Therapeutics, Inc. - Common Stock
$38,83
▲ +$1,04
(+2,75%)
Vol. 811K
2
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$913.9M
ROE
-24,9%
D/E
0,00
Beta
0,27
52W
$13–$25
Consenso Wall Street
16 analisti · Apr 20265
Acquisto forte
10
Compra
1
Mantieni
0
Vendi
0
Vendita forte
93,8%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 50,0%
Prossimo report
Mag 12, 2026
Stima EPS: $-0,47
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,47 | — | — |
| Dic 2025 | $-0,39 | $-0,48 | $-0,09 |
| Set 2025 | $-0,44 | $-0,32 | +$0,12 |
| Giu 2025 | $-0,54 | $-0,49 | +$0,05 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — | — |
| Utile netto | — | -$23.2M | -$28.5M | -$25.3M | -$20.1M | -$29.7M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -29.1% | -31.8% | -29.1% | -29.1% | -29.1% | -24.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 32.58 | 21.06 | 32.58 | 32.58 | 32.58 | 32.95 |
Rapporti chiave
ROA (TTM)
-24,0%
P/B
3,5
EPS (TTM)
$-1,85
CF/Share
$-0,72
52W High
$25,37
52W Low
$13,30
$13,30
Intervallo 52 settimane
$25,37
Salute finanziaria
Flusso di cassa libero
-$15.8M
Debito netto
-$98.5M
Liquidità
$98.9M
Debito totale
$399K
Aggiornato al Dic 31, 2025
Як ELVN виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка ELVN vs аналоги Pharmaceuticals
P/E
—
▼
0%
sotto
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
—
▼
0%
sotto
peer
(5,0)
vs Peer
vs Settore
Sopravvalutato
P/B
3,6
▲
67%
sopra
peer
(2,1)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ELVN vs аналоги Pharmaceuticals
ROE
-24,9%
▲
54%
sopra
peer
(-54,3%)
vs Peer
vs Settore
Sotto media
Net margin
—
▼
0%
sotto
peer
(-47,4%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(68,3%)
vs Peer
vs Settore
In linea
ROA
-24,0%
▲
36%
sopra
peer
(-37,4%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя ELVN vs аналоги Pharmaceuticals
D/E ratio
0,0
▼
100%
sotto
peer
(1,5)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
33,0
▲
881%
sopra
peer
(3,4)
vs Peer
vs Settore
Liquidità forte
Beta
0,3
▼
71%
sotto
peer
(0,9)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ELVN
ELVN
Mediana peer
Industria
ELVN прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ELVN vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
COLLINS HELEN LOUISE
Officer · Mar 25
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 25
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 17
5000 shs
COLLINS HELEN LOUISE
Officer · Mar 17
5000 shs
COLLINS HELEN LOUISE
Officer · Mar 10
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 10
40000 shs
HOHL BENJAMIN
Chief Financial Officer · Mar 06
10000 shs
COLLINS HELEN LOUISE
Officer · Feb 17
45000 shs
HEYMAN RICHARD A
Director · Feb 17
1230 shs
COLLINS HELEN LOUISE
Officer · Feb 17
45000 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 45,66%Orbimed Advisors LLC.
13,31%
$309.1M
FMR, LLC
11,89%
$276.0M
Commodore Capital Lp
7,85%
$182.2M
Vestal Point Capital, LP
6,40%
$148.7M
Fairmount Funds Management …
6,21%
$144.1M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora